PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
about
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyPD-L1 Status in Refractory Lymphomas.Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelMonitoring immune-checkpoint blockade: response evaluation and biomarker development.Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.Correlation of immune phenotype with IDH mutation in diffuse glioma.Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.Targeting the programmed death-1 pathway in lymphoid neoplasms.PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome.Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomePD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.In search of a target: PD-1 and PD-L1 profiling across glioma types.Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma.Do immune checkpoint inhibitors need new studies methodology?
P2860
Q36043066-DBFD1B71-7B9E-45DB-B3CD-8C86ACA2AF6DQ36197517-78D5DFF3-898A-4B3F-BCAF-0B20FF6C9B0AQ37362623-3993B1E9-0391-4ED8-91BA-58C01F518EC4Q37376269-BAFE2228-8168-4547-88BB-7F73D71C18C6Q38666241-2004AAD6-3DAF-46F2-BCA8-FBE6FE96FCE7Q38687867-0A525E0B-02B9-481D-9FF1-723EA54D15ECQ38742013-0519A9A1-3EEC-474B-956B-C8F1459A9E3CQ38771020-4ABAEBBF-0B65-4EDE-B4F0-9D9430F6E216Q38830663-1FA04A56-6178-461B-B7F6-04EAB08B1EEBQ39038545-7C5B8458-6D90-42D4-A70C-14AE93151485Q39153358-14924264-E872-47D8-BB75-2F6E538C2514Q39452745-78BF4766-656B-437A-A4A8-018CB1ACE68EQ39583147-10EE8615-66B2-4E6C-A108-EE2109F308BCQ40223999-3C4DAB02-D118-4025-B4B7-00E13925ABA6Q41069147-427C708A-D980-41CF-8338-CFABBA7E8D0BQ41550899-3AC6CAB1-74D3-4392-BE7C-DB4E072EB528Q41708934-F2194DB4-B325-4DC7-A768-62ED4087E85DQ42289790-692C1B09-58B2-4568-8227-3E7916078426Q42371630-667177BD-31B1-43F4-96A7-243E85A92D7CQ42391407-ACA6BFB7-8785-408C-A5E4-1326A31A4A51Q45064344-FF852FD4-84D0-4571-A116-96164D688BD1Q47142947-F7A6BCD0-AA43-4A68-A62E-731012E1009DQ47261543-2BFA6038-812E-4EBF-9170-5AC7DD590304Q47861303-175A00F7-F8C1-4ACD-AF45-EFB8D1849351Q48088758-EB95C5D5-0683-4E29-B4C7-49FF01CFC3E2Q49374190-70A6005B-AF00-47E0-AB07-6DD67A1A0D71Q50076875-504930A4-814D-4E55-9707-C09154B7337DQ50089792-9684CF86-74E5-4EFF-9921-647E5C254359Q52316792-2B163072-03B5-41DD-BB37-DA73F8C5A4E0Q53488547-CD1480A2-C81C-4153-B8E9-BAD28DC41CFBQ55262931-599A016E-7AB0-465D-9DA3-32105B3EC40AQ55375458-1594F7E0-8708-4C2B-BFAC-CEE5A8EBEA30
P2860
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
PD-L1 Antibodies to Its Cytopl ...... mical Staining of Tumor Cells.
@en
type
label
PD-L1 Antibodies to Its Cytopl ...... mical Staining of Tumor Cells.
@en
prefLabel
PD-L1 Antibodies to Its Cytopl ...... mical Staining of Tumor Cells.
@en
P2093
P2860
P1476
PD-L1 Antibodies to Its Cytopl ...... mical Staining of Tumor Cells.
@en
P2093
Arlene H Sharpe
Edward A Greenfield
F Stephen Hodi
Gordon J Freeman
Heather Sun
Kathleen M Mahoney
Marcella Callea
Sabina Signoretti
Scott J Rodig
P2860
P304
P356
10.1158/2326-6066.CIR-15-0116
P577
2015-11-06T00:00:00Z